Open, laparoscopic, and robotic liver resection for hepatocellular carcinoma: evolving roles, comparative outcomes, and future perspectives
- 1AdventHealth Tampa, Digestive Health Institute
Abstract
Hepatocellular carcinoma remains one of the leading causes of cancer-related mortality worldwide and frequently arises in the setting of chronic liver disease, cirrhosis, and portal hypertension. Liver resection represents a cornerstone of curative-intent treatment, but its role is uniquely influenced by the need to balance oncologic radicality with preservation of functional liver parenchyma. Over the last two decades, minimally invasive liver surgery has progressively expanded from selected laparoscopic minor resections to complex laparoscopic and robotic hepatectomies, challenging the historical dominance of open surgery. This narrative review critically examines the evolving roles of open, laparoscopic, and robotic liver resection for hepatocellular carcinoma, emphasizing patient selection, technical considerations, scenario-based platform choice, and comparative outcomes. Particular attention is given to hepatocellular carcinoma-specific challenges, including impaired liver function, clinically significant portal hypertension, future liver remnant adequacy, recurrence risk, and the need for parenchymal-sparing strategies. The review also discusses distinct clinical scenarios, including small solitary tumors, posterosuperior lesions, central or deeply located tumors, multifocal disease, and recurrent HCC. Current evidence consistently suggests that minimally invasive approaches are associated with reduced blood loss, fewer postoperative complications, and shorter hospital stay compared with open surgery, while maintaining comparable oncologic outcomes in selected patients. Laparoscopy remains the most established minimally invasive platform, whereas robotics may offer technical advantages in complex resections through improved dexterity, three-dimensional visualization, and enhanced suturing capability. However, available evidence remains largely retrospective and influenced by selection bias and institutional expertise. Platform selection should therefore be individualized according to tumor anatomy, liver function, technical complexity, and center experience, with the goal of maximizing oncologic benefit while minimizing functional liver loss.
Related
- Impact of Laparoscopic Liver Resection on Long‐Term Outcomes and Non‐Liver‐Related Mortality in Elderly Patients With Primary Hepatocellular Carcinoma: A Multicenter Propensity Score‐Matched Analysis
- Indocyanine green fluorescence–guided laparoscopic anatomical hepatectomy for radical resection of hepatocellular carcinoma: a clinical study
- Peri-interventional neutrophil extracellular traps and immune surveillance in hepatocellular carcinoma: mechanisms, biomarkers, and recurrence after liver resection or thermal ablation
- Association of steatotic liver disease with long-term oncological outcomes after hepatic resection for hepatocellular carcinoma
- Pfannenstiel versus periumbilical specimen extraction in laparoscopic low anterior resection: a comparative analysis of incisional hernia risk, postoperative recovery, and oncologic outcomes.
BibTeX
@article{mascherini2026open,
title = {{Open, laparoscopic, and robotic liver resection for hepatocellular carcinoma: evolving roles, comparative outcomes, and future perspectives}},
author = {Jacopo Mascherini and Mira Khaldoun Eid and Garnet Vanterpool and Iswanto Sucandy},
journal = {Frontiers in Oncology},
year = {2026},
month = oct,
doi = {10.3389/fonc.2026.1936469},
url = {https://www.frontiersin.org/articles/10.3389/fonc.2026.1936469/full},
note = {CC BY 4.0},
}
RIS
TY - JOUR
TI - Open, laparoscopic, and robotic liver resection for hepatocellular carcinoma: evolving roles, comparative outcomes, and future perspectives
AU - Jacopo Mascherini
AU - Mira Khaldoun Eid
AU - Garnet Vanterpool
AU - Iswanto Sucandy
PY - 2026
DA - 2026/10/08
JO - Frontiers in Oncology
DO - 10.3389/fonc.2026.1936469
UR - https://www.frontiersin.org/articles/10.3389/fonc.2026.1936469/full
AB - Hepatocellular carcinoma remains one of the leading causes of cancer-related mortality worldwide and frequently arises in the setting of chronic liver disease, cirrhosis, and portal hypertension. Liver resection represents a cornerstone of curative-intent treatment, but its role is uniquely influenced by the need to balance oncologic radicality with preservation of functional liver parenchyma. Over the last two decades, minimally invasive liver surgery has progressively expanded from selected laparoscopic minor resections to complex laparoscopic and robotic hepatectomies, challenging the historical dominance of open surgery. This narrative review critically examines the evolving roles of open, laparoscopic, and robotic liver resection for hepatocellular carcinoma, emphasizing patient selection, technical considerations, scenario-based platform choice, and comparative outcomes. Particular attention is given to hepatocellular carcinoma-specific challenges, including impaired liver function, clinically significant portal hypertension, future liver remnant adequacy, recurrence risk, and the need for parenchymal-sparing strategies. The review also discusses distinct clinical scenarios, including small solitary tumors, posterosuperior lesions, central or deeply located tumors, multifocal disease, and recurrent HCC. Current evidence consistently suggests that minimally invasive approaches are associated with reduced blood loss, fewer postoperative complications, and shorter hospital stay compared with open surgery, while maintaining comparable oncologic outcomes in selected patients. Laparoscopy remains the most established minimally invasive platform, whereas robotics may offer technical advantages in complex resections through improved dexterity, three-dimensional visualization, and enhanced suturing capability. However, available evidence remains largely retrospective and influenced by selection bias and institutional expertise. Platform selection should therefore be individualized according to tumor anatomy, liver function, technical complexity, and center experience, with the goal of maximizing oncologic benefit while minimizing functional liver loss.
SN - 2234-943X
ER -